Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis
OncLive,
Imetelstat Plus Ruxolitinib in Myelofibrosis | Image Credit: © Свет Лана – stock.adobe.com The safety profile of imetelstat (Ryte…
Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of…
Overview of attention for article published in Blood, November 2024
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (78th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)
Readers on
- mendeley
- 2 Mendeley